FDA Status
Not FDA-Approved
Russian bioregulator (SPIBG)
Claimed Benefits
- Lifespan extension (preclinical)
- Anti-tumor activity (preclinical)
- Immune recovery
- SIRT1/PARP gene regulation
Clinical Evidence
8
Human Trials
Clinical Evaluation
Highest Phase
Extended lifespan and inhibited tumor growth in mice; a 2023 human stem cell study identified SIRT1 and PARP regulation.
Read Full Deep Dive
Mechanism, dosing, vendor pricing, and full research citations